J. W. Coons Advisors LLC Raises Stake in Gilead Sciences, Inc. (NASDAQ:GILD)

J. W. Coons Advisors LLC boosted its holdings in Gilead Sciences, Inc. (NASDAQ:GILDFree Report) by 2.8% during the 4th quarter, according to its most recent disclosure with the SEC. The firm owned 11,130 shares of the biopharmaceutical company’s stock after buying an additional 300 shares during the period. J. W. Coons Advisors LLC’s holdings in Gilead Sciences were worth $902,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Tompkins Financial Corp increased its stake in Gilead Sciences by 223.1% during the 3rd quarter. Tompkins Financial Corp now owns 349 shares of the biopharmaceutical company’s stock worth $26,000 after buying an additional 241 shares during the period. Private Wealth Management Group LLC bought a new stake in Gilead Sciences in the fourth quarter valued at about $29,000. Fortitude Family Office LLC bought a new stake in shares of Gilead Sciences in the 4th quarter valued at approximately $29,000. Sachetta LLC acquired a new stake in shares of Gilead Sciences during the fourth quarter worth $30,000. Finally, Rakuten Securities Inc. bought a new stake in shares of Gilead Sciences during the 4th quarter valued at about $33,000. 83.67% of the stock is owned by institutional investors and hedge funds.

Insider Transactions at Gilead Sciences

In related news, insider Merdad Parsey sold 2,000 shares of the stock in a transaction that occurred on Monday, April 1st. The stock was sold at an average price of $72.96, for a total transaction of $145,920.00. Following the completion of the sale, the insider now owns 96,304 shares in the company, valued at approximately $7,026,339.84. The sale was disclosed in a filing with the SEC, which is available through the SEC website. 0.16% of the stock is currently owned by corporate insiders.

Gilead Sciences Trading Up 1.3 %

Gilead Sciences stock opened at $64.70 on Friday. Gilead Sciences, Inc. has a one year low of $62.07 and a one year high of $87.86. The company’s fifty day moving average price is $66.66 and its two-hundred day moving average price is $73.71. The company has a market capitalization of $80.61 billion, a price-to-earnings ratio of 179.72, a PEG ratio of 1.28 and a beta of 0.20. The company has a debt-to-equity ratio of 1.31, a current ratio of 1.08 and a quick ratio of 0.94.

Gilead Sciences (NASDAQ:GILDGet Free Report) last issued its quarterly earnings data on Thursday, April 25th. The biopharmaceutical company reported ($1.32) earnings per share for the quarter, topping analysts’ consensus estimates of ($1.49) by $0.17. Gilead Sciences had a net margin of 1.76% and a return on equity of 24.34%. The business had revenue of $6.69 billion during the quarter, compared to analysts’ expectations of $6.36 billion. During the same period in the previous year, the company earned $1.37 earnings per share. Gilead Sciences’s revenue for the quarter was up 5.3% on a year-over-year basis. On average, analysts forecast that Gilead Sciences, Inc. will post 3.75 earnings per share for the current fiscal year.

Gilead Sciences Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Thursday, June 27th. Stockholders of record on Friday, June 14th will be given a $0.77 dividend. This represents a $3.08 annualized dividend and a dividend yield of 4.76%. The ex-dividend date is Friday, June 14th. Gilead Sciences’s dividend payout ratio is currently 855.56%.

Wall Street Analyst Weigh In

GILD has been the topic of a number of recent research reports. UBS Group cut their target price on shares of Gilead Sciences from $81.00 to $75.00 and set a “neutral” rating on the stock in a report on Wednesday, April 17th. Needham & Company LLC reiterated a “hold” rating on shares of Gilead Sciences in a research report on Friday, April 26th. Maxim Group reduced their price target on shares of Gilead Sciences from $90.00 to $85.00 and set a “buy” rating for the company in a research note on Wednesday, May 1st. Mizuho decreased their target price on Gilead Sciences from $101.00 to $90.00 and set a “buy” rating for the company in a research note on Thursday, February 22nd. Finally, Wells Fargo & Company decreased their price target on shares of Gilead Sciences from $84.00 to $77.00 and set an “equal weight” rating on the stock in a research report on Monday, March 4th. Eleven equities research analysts have rated the stock with a hold rating, six have given a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat, Gilead Sciences currently has an average rating of “Hold” and an average price target of $83.69.

Check Out Our Latest Stock Analysis on Gilead Sciences

About Gilead Sciences

(Free Report)

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.

See Also

Institutional Ownership by Quarter for Gilead Sciences (NASDAQ:GILD)

Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.